In vitro metabolic profile and in vivo antischistosomal activity studies of (η6-praziquantel)Cr(CO)3 derivatives

Journal of Medicinal Chemistry

Volumn 56, Issue 22, 2013, Pages 9192-9198

  Patra, Malay ^a   Ingram, Katrin ^c   Leonidova, Anna ^a   Pierroz, Vanessa ^a,b   Ferrari, Stefano ^b   Robertson, Murray N ^d   Todd, Matthew H ^d   Keiser, Jennifer ^c   Gasser, Gilles ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DIAZEPAM; PRAZIQUANTEL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ANTISCHISTOSOMAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; LIVER MICROSOME METABOLISM; MASS SPECTROMETRY; METABOLIC RATE; MOUSE; NONHUMAN; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ANIMALS; ANTHELMINTICS; FEMALE; HUMANS; MICE; OPTICAL PROCESSES; PRAZIQUANTEL; SCHISTOSOMA MANSONI; STEREOISOMERISM; SUBSTRATE SPECIFICITY;

EID: 84889256318     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401287m     Document Type: Article

References (36)

1. Gryseels, B. Schistosomiasis Infect. Dis. Clin. North Am. 2012, 26, 383-397
2. Steinmann, P.; Keiser, J.; Bos, R.; Tanner, M.; Utzinger, J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk The Lancet Infect. Dis. 2006, 6, 411-425 (Pubitemid 43949139)
3. Thétiot-Laurent, S. A. L.; Boissier, J.; Robert, A.; Meunier, B. Schistosomiasis chemotherapy Angew. Chem., Int. Ed. 2013, 52, 7936-7956
4. Ismail, M.; Botros, S.; Metwally, A.; William, S.; Farghally, A.; Tao, L. F.; Day, T. A.; Bennett, J. L. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers Am. J. Trop. Med. Hyg. 1999, 60, 932-935 (Pubitemid 29296217)
5. Melman, S. D.; Steinauer, M. L.; Cunningham, C.; Kubatko, L. S.; Mwangi, I. N.; Wynn, N. B.; Mutuku, M. W.; Karanja, D. M. S.; Colley, D. G.; Black, C. L.; Secor, W. E.; Mkoji, G. M.; Loker, E. S. Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni PLoS Neglected. Trop. Dis. 2009, 3, e504
6. Greenberg, R. M. New approaches for understanding mechanisms of drug resistance in schistosomes Parasitology 2013, 140, 1534-1546
7. Cioli, D.; Pica-Mattoccia, L.; Archer, S. Antischistosomal drugs: past, present.. and future? Pharmacol. Ther. 1995, 68, 35-85
8. Huang, J.; Bathena, S. P. R.; Alnouti, Y. Metabolite profiling of praziquantel and its analogs during the analysis of in vitro metabolic stability using information-dependent acquisition on a hybrid triple quadrupole linear ion trap mass spectrometer Drug Metab. Pharmacokinet. 2010, 25, 487-499
9. Doenhoff, M. J.; Cioli, D.; Utzinger, J. Praziquantel: Mechanisms of action, resistance and new derivatives for schistosomiasis Curr. Opin. Infect. Dis. 2008, 21, 659-667
10. Hillard, E. A.; Vessières, A.; Jaouen, G. Ferrocene functionalized endocrine modulators as anticancer agents. In Medicinal Organometallic Chemistry; Jaouen, G.; Metzler-Nolte, N., Eds.; Springer-Verlag: Heidelberg, Germany, 2010; Vol. 32, pp 81-117.
11. Dive, D.; Biot, C. Ferrocene conjugates of chloroquine and other antimalarials: The development of ferroquine, a new antimalarial ChemMedChem 2008, 3, 383-391
12. Hillard, E.; Vessieres, A.; Thouin, L.; Jaouen, G.; Amatore, C. Ferrocene-mediated proton-coupled electron transfer in a series of ferrocifen-type breast-cancer drug candidates Angew. Chem., Int. Ed. 2006, 45, 285-290 (Pubitemid 43017528)
13. Dubar, F.; Egan, T. J.; Pradines, B.; Kuter, D.; Ncokazi, K. K.; Forge, D.; Paul, J.-F.; Pierrot, C.; Kalamou, H.; Khalife, J.; Buisine, E.; Rogier, C.; Vezin, H.; Forfar, I.; Slomianny, C.; Trivelli, X.; Kapishnikov, S.; Leiserowitz, L.; Dive, D.; Biot, C. The antimalarial ferroquine: Role of the metal and intramolecular hydrogen bond in activity and resistance ACS Chem. Biol. 2012, 6, 275-287
14. Patra, M.; Ingram, K.; Pierroz, V.; Ferrari, S.; Spingler, B.; Keiser, J.; Gasser, G. Ferrocenyl derivatives of the anthelmintic praziquantel: Design, synthesis and biological evaluation J. Med. Chem. 2012, 55, 8790-8798
15. 3 derivatives with remarkable in vitro antischistosomal activity Chem. Eur. J. 2013, 19, 2232-2235
16. Kiec-Kononowicz, K.; Farghaly, Z. S.; Blaschke, G. Synthesis and properties of cis- and trans-4-hydroxypraziquantel Arch. Pharm. (Weinheim) 1991, 324, 235-237
17. Lerch, C.; Blaschke, G. Investigation of the stereoselective metabolism of praziquantel after incubation with rat liver microsomes by capillary electrophoresis and liquid chromatography-mass spectrometry J. Chromatogr. B 1998, 708, 267-275 (Pubitemid 28239914)
18. Diekmann, H. W. Quantitative determination of praziquantel in body fluids by gas liquid chromatography Eur. J. Drug Metab. Pharmacokinet. 1979, 4, 139-141 (Pubitemid 10164993)
19. Andrews, P.; Thomas, H.; Pohlke, R.; Seubert, J. Praziquantel Med. Res. Rev. 1983, 3, 147-200 (Pubitemid 13059325)
20. Steiner, K.; Garbe, A.; Diekmann, H. W.; Nowak, H. The fate of praziquantel in the organism I. Pharmacokinetics in animals Eur. J. Drug Metab. Pharmacokin. 1976, 1, 85-95 (Pubitemid 8072126)
21. Meier, H.; Blaschke, G. Investigation of praziquantel metabolism in isolated rat hepatocytes J. Pharm. Biomed. Anal. 2001, 26, 409-415 (Pubitemid 32727659)
22. Schepmann, D.; Blaschke, G. Isolation and identification of 8-hydroxypraziquantel as a metabolite of the antischistosomal drug praziquantel J. Pharm. Biomed. Anal. 2001, 26, 791-799 (Pubitemid 32971690)
23. Godawska-Matysik, A.; Kieć-Kononowicz, K. Biotransformation of praziquantel by human cytochrome P450 3A4 (CYP 3A4) Acta Pol. Pharm. 2006, 63, 381-385
24. Woelfle, M.; Seerden, J.-P.; de Gooijer, J.; Pouwer, K.; P., O.; Todd, M. H. Resolution of Praziquantel PLoS Neglected Trop. Dis. 2011, 5, e1260
25. Chan, J. D.; Zarowiecki, M.; Marchant, J. S. Ca(2+) channels and praziquantel: A view from the free world Parasitol. Int. 2013, 62, 619-628
26. Keiser, J.; Chollet, J.; Xiao, S.-H.; Mei, J.-Y.; Jiao, P.-Y.; Utzinger, J.; Tanner, M. Mefloquine-An aminoalcohol with promising antischistosomal properties in mice PLoS Neglected Trop. Dis. 2009, 3, e350
27. Assem, L.; Zhu, H. Chromium; toxicicological overview, 2007; Health Protection Agency, http://www.hpa.org.uk/webc/HPAwebFile/HPAweb-C/1194947362170.
28. Levina, A.; Lay, P. A. Metal-based anti-diabetic drugs: advances and challenges Dalton Trans. 2011, 40, 11675-11686 and references therein.
29. Jaouen, G.; Metzler-Nolte, N. Medicinal Organometallic Chemistry. In Topics in Organometallic Chemistry, 1 st ed.; Springer: Heidelberg, Germany, 2010; Vol. 32.
30. Hartinger, C. G.; Metzler-Nolte, N.; Dyson, P. J. Challenges and opportunities in the development of organometallic anticancer drugs Organometallics 2012, 31, 5677-5685
31. Dong, Y.; Chollet, J.; Vargas, M.; Mansour, N. R.; Bickle, Q.; Alnouti, Y.; Huang, J.; Keiser, J.; Vennerstrom, J. L. Praziquantel analogs with activity against juvenile Schistosoma mansoni Bioorg. Med. Chem. Lett. 2010, 20, 2481-2484
32. Laurent, S. A.-L.; Boissier, J.; Coslédan, F.; Gornitzka, H.; Robert, A.; Meunier, B. Synthesis of "Trioxaquantel"® derivatives as potential new antischistosomal drugs Eur. J. Org. Chem. 2008, 895-913
33. Keiser, J. In vitro and in vivo trematode models for chemotherapeutic studies Parasitology 2009, 137, 589-603
34. Xiao, S.-H.; Keiser, J.; Chollet, J.; Utzinger, J.; Dong, Y.; Endriss, Y.; Vennerstrom, J. L.; Tanner, M. In vitro and in vivo activities of synthetic trioxolanes against major human schistosome species Antimicrob. Agents Chemother. 2007, 51, 1440-1445 (Pubitemid 46586827)
35. Ingram, K.; Ellis, W.; Keiser, J. Antischistosomal activities of mefloquine-related arylmethanols Antimicrob. Agents Chemother. 2012, 56, 3207-3215
36. Ramirez, B.; Bickle, Q.; Yousif, F.; Fakorede, F.; Mouries, M.-A.; Nwaka, S. Schistosomes: Challenges in compound screening Expert Opin. Drug Discovery 2007, 2, S53-S61